News Roundup this Week

• Novo's Wegovy and Ozempic removed from US FDA shortage list, compounders on notice
  The U.S. Food and Drug Administration (FDA) has declared that the shortages of Novo Nordisk's popular weight-loss and diabetes medications, Wegovy and Ozempic, have been resolved. Shares of companies offering such compounded medications, like Hims & Hers Health, experienced significant declines following the FDA's update. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-says-shortage-novos-weight-loss-drug-resolved-2025-02-21/
  

• Lilly, Novo Fight Weight Loss Drug Compounders Over Shortage
  Eli Lilly & Co. and Novo Nordisk A/S are asking a federal court to reject legal protections to drug compounders making copycat versions of the weight loss drug Tirzepatide. The Outsourcing Facilities Association and FarmaKeio Custom Compounding filed in January a motion for preliminary injunction in the US District Court for the Northern District of Texas that would prohibit the FDA from taking any action against them while they compound Tirzepatide.
  https://news.bloomberglaw.com/health-law-and-business/lilly-novo-fight-weight-loss-drug-compounders-over-shortage
  

• Telehealth Firm Hims & Hers Extends Compounding Window
  On February 20, 2025, CNBC noted that Hims & Hers can continue using its compounding facilities for drugs like Semaglutide until May 22, per the FDA’s latest decision. This reflects a broader trend of telehealth leveraging compounding to meet demand, with the firm’s next earnings due February 24.
  

• Pharmacy closures create growing “desert” in rural Maine
  Pharmacy closures are increasingly leaving rural Maine communities without local access to essential medications, creating "pharmacy deserts." Both independent and chain pharmacies have been shutting down, intensifying the issue. https://wgme.com/news/i-team/pharmacy-closures-create-growing-desert-in-rural-maine

Featured Compounding Formula

Featured Blog Post

 Thank you